Record mula sa primary source
Decision-gradeTopline na resulta
ADCT: Nakamit ng LOTIS-5 Phase 3 topline ang endpoint ng PFS para sa ZYNLONTA + rituximab
Natugunan ng Phase 3 LOTIS-5 trial ang pangunahing endpoint ng PFS nito na may istatistikang kahalagahan (HR 0.73, p=0.008). Plano ng ADC Therapeutics ang isang pre-sBLA meeting sa FDA sa Agosto 2026 at isang pagsusumite ng sBLA sa Q4 2026 upang humingi ng buong pag-apruba para sa ZYNLONTA kasama ang rituximab sa r/r DLBCL.
Mahahalagang fact
- Na-file
- Hun 3, 2026, 08:17 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
ADCTADC Therapeutics- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- HR
- 0.73
- CR rate
- 39.5% vs 26.7%
- p-value
- 0.008
- median PFS
- 6.1 vs 4.7 months
- median docr
- 16.8 vs 12.3 months
Sipi mula sa source
false 0001771910 0001771910 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2026 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/A (IRS Employer Identification Number) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) + 41 21 653 02 00 (Registrant’s Telephone Number) N/A (Former Name or Former Address, if Changed Since Last Report) Ch
Higit pa tungkol sa asset na ito
Decision-grade
Ago 13, 2026
01:14 PM
ADCTADC Therapeutics